|
Very low-dose (75 mg twice daily)
|
3
|
23
|
5.73 [1.55–21.2], (0.009*)
|
|
Age, years
|
77.4 ± 13.5
|
71.0 ± 10.8
|
1.06 [1.01–1.12], (0.013*)
|
|
Gender, female
|
10
|
234
|
2.40 [0.93–6.16], (0.069)
|
|
Creatinine clearance: Ccr (mL/min)
|
58.9 ± 23.5
|
69.0 ± 25.3
|
0.98 [0.96–1.02], (0.096)
|
|
History of bleeding
|
1
|
78
|
0.46 [0.06–3.45], (0.449)
|
|
New users
|
8
|
346
|
1.28 [0.50–3.29], (0.604)
|
|
Change from warfarin
|
8
|
224
|
1.66 [0.65–4.27], (0.292)
|
|
C: Congestive heart failure
|
6
|
132
|
1.84 [0.67–4.99], (0.233)
|
|
H: Hypertension
|
9
|
417
|
0.56 [0.22–1.45], (0.231)
|
|
A: Aged 75 or older
|
13
|
281
|
3.16 [1.11–8.96], (0.031*)
|
|
D: Diabetes Mellitus
|
5
|
135
|
1.36 [0.47–3.90], (0.561)
|
|
S: Stroke/TIA (2 points)
|
10
|
175
|
3.24 [1.26–8.36], (0.015*)
|
|
CHADS2 score
|
2.94 ± 1.51
|
1.92 ± 1.34
|
1.69 [1.21–2.37], (0.002*)
|
|
With antiplatelet agents
|
2
|
127
|
0.55 [0.12–2.43], (0.426)
|
